bluebird bio Inc (NASDAQ:BLUE) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: October 8, 2016
Zacks Investment Research has downgraded bluebird bio Inc (NASDAQ:BLUE) to Sell in a statement released on 10/05/2016.
On 09/29/2016, Maxim Group released a statement on bluebird bio Inc (NASDAQ:BLUE) upped the target price from $85.00 to $100.00 that suggested an upside of 0.50%.
Having a price of $73.12, bluebird bio Inc (NASDAQ:BLUE) traded -0.47% lower on the day. With the last close up 39.02% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. BLUE has recorded a 50-day moving average of $61.78 and a 200-day moving average of $50.12. 940,729 shares of BLUE traded hands, down from an average trading volume of 1,111,730
Recent Performance Chart
bluebird bio Inc has 52 week low of $35.37 and a 52 week high of $99.70 and has a market capitalization of $0.
A total of 14 brokerages have issued a ratings update on bluebird bio Inc. Six brokerages rating the company a strong buy, six brokerages rating the company a buy, three brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $89.07.
General Company Details For bluebird bio Inc (NASDAQ:BLUE)
bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.